Is Boston Scientific Corp (BSX) overvalued? · P/E 20, rev $16.75B
Boston Scientific Corp (BSX) is a medical devices company listed on US.
This page asks whether Boston Scientific Corp (BSX) looks expensive on cached numbers — not a short thesis.
Latest reported BSX revenue for 2024-12-31 was $16.75B. Net income was $1.85B. Revenue was up 17.6% from 2023-12-31 to 2024-12-31. BSX currently screens at market cap $71.81B and trailing P/E 20.2.
BSX currently screens at market cap $71.81B and trailing P/E 20.2. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next BSX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the BSX stock page for the full model, not this heading.
Not investment advice.